Kevin Outterson, JD, LLM
Professor of Law and N. Neal Pike Scholar
Boston University School of Law
Dept of Health and Disability Law

LLM, University of Cambridge
JD, Northwestern University School of Law




Research interests in pharmaceutical innovation, including the law & economics of antimicrobial resistance.

Associate Professor of Health Law, Ethics & Human Rights
Boston University School of Public Health
Health Law, Policy & Management
Center for Health Law, Ethics & Human Rights

Executive Director of CARB-X
Boston University School of Law
Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X)




Accelerating the Development ofinnovative Preventive Approaches to Combat AMR
05/18/2018 - 05/31/2023 (PI)
Bill and Melinda Gates Foundation


VALUE-Dx
04/01/2019 - 03/31/2023 (Multi-PI)
PI: Kevin Outterson, JD, LLM
University of Antwerp European Commission


Accelerating the Development of innovative Preventive Approaches to Combat AMR
01/01/2019 - 12/31/2022 (PI)
The German Federal Ministry of Education and Research


RESTRICTED: Accelerating the Development of Innovative Preventive Approaches to Combat AMR
01/01/2019 - 12/31/2022 (PI)
The German Federal Ministry of Education and Research


WT CARB-X Core Mgmt/Other Program Support
01/01/2019 - 07/31/2022 (PI)
Wellcome Trust


WT CARB-X PD/Acc Costs Cost-Share
04/01/2017 - 07/31/2022 (PI)
Wellcome Trust


WT CARB-X Non Awardee Costs
04/01/2017 - 07/31/2022 (PI)
Wellcome Trust


CARB-X
08/01/2016 - 07/31/2022 (PI)
HHS/Assistant Secretary for Preparedness and Response
6 IDSEP160030-05-07

CARB-X/ UK GAMRIF
05/18/2018 - 03/31/2022 (PI)
Department of Health and Social Care




Title


Yr Title Project-Sub Proj Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Outterson K, Orubu ESF, Rex J, Årdal C, Zaman MH. Patient Access in 14 High-Income Countries to New Antibacterials Approved by the US Food and Drug Administration, European Medicines Agency, Japanese Pharmaceuticals and Medical Devices Agency, or Health Canada, 2010-2020. Clin Infect Dis. 2022 Apr 09; 74(7):1183-1190. PMID: 34251436
     
  2. Rex JH, Outterson K. Antibacterial R&D at a Crossroads: We've Pushed as Hard as We Can … Now We Need to Start Pulling! Clin Infect Dis. 2021 12 06; 73(11):e4451-e4453. PMID: 32584949
     
  3. Outterson K. Estimating The Appropriate Size Of Global Pull Incentives For Antibacterial Medicines. Health Aff (Millwood). 2021 11; 40(11):1758-1765. PMID: 34724432
     
  4. Nanayakkara AK, Boucher HW, Fowler VG, Jezek A, Outterson K, Greenberg DE. Antibiotic resistance in the patient with cancer: Escalating challenges and paths forward. CA Cancer J Clin. 2021 11; 71(6):488-504. PMID: 34546590
     
  5. Colson AR, Morton A, Årdal C, Chalkidou K, Davies SC, Garrison LP, Jit M, Laxminarayan R, Megiddo I, Morel C, Nonvignon J, Outterson K, Rex JH, Sarker AR, Sculpher M, Woods B, Xiao Y. Antimicrobial Resistance: Is Health Technology Assessment Part of the Solution or Part of the Problem? Value Health. 2021 12; 24(12):1828-1834. PMID: 34838281
     
  6. Kållberg C, Hudson J, Salvesen Blix H, Årdal C, Klein E, Lindbæk M, Outterson K, Røttingen JA, Laxminarayan R. The effect of generic market entry on antibiotic prescriptions in the United States. Nat Commun. 2021 05 18; 12(1):2937. PMID: 34006862; PMCID: PMC8131704; DOI: 10.1038/s41467-021-23049-4;
     
  7. Boucher HW, File TM, Fowler VG, Jezek A, Rex JH, Outterson K. Antibiotic Development Incentives That Reflect Societal Value of Antibiotics. Clin Infect Dis. 2021 05 04; 72(9):e420-e421. PMID: 31999818
     
  8. Puzniak L, Gupta V, Yu KC, Ye G, Outterson K. The impact of infections on reimbursement in 92 US hospitals, 2015-2018. Am J Infect Control. 2021 10; 49(10):1275-1280. PMID: 33891989
     
  9. Kim W, Krause K, Zimmerman Z, Outterson K. Improving data sharing to increase the efficiency of antibiotic R&D. Nat Rev Drug Discov. 2021 01; 20(1):1-2. PMID: 33097914
     
  10. Minssen T, Outterson K, Rogers Van Katwyk S, Batista PHD, Chandler CIR, Ciabuschi F, Harbarth S, Kesselheim AS, Laxminarayan R, Liddell K, Osterholm MT, Price L, Hoffman SJ. Social, cultural and economic aspects of antimicrobial resistance. Bull World Health Organ. 2020 Dec 01; 98(12):823-823A. PMID: 33293739; PMCID: PMC7716096; DOI: 10.2471/BLT.20.275875;
     
Showing 10 of 85 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 85 publications over 21 distinct years, with a maximum of 9 publications in 2011

YearPublications
19981
20031
20041
20058
20064
20071
20083
20098
20105
20119
20123
20132
20141
20155
20166
20174
20183
20196
20205
20218
20221


Recent (within 3 months)

Antimicrobial Resistance: What’s At Stake And What Are We Doing About It?

Health Affairs 3/4/2022

Older

The World’s Next Big Health Emergency Is Already Here

The Washington Post 1/27/2022

Drug-Resistant Superbugs Are Causing More Deaths: What’s Being Done?

Healthline 1/26/2022

VIDEO: Sustainable funding of antibiotic development

Healio 11/11/2021

Pfizer buys Amplyx to expand drug-resistant treatment portfolio

Reuters 4/28/2021

The next pandemic? It may already be upon us

The Guardian 2/15/2021

Biden must act quickly to defeat another pandemic

The Boston Herald 2/14/2021

Push and pull: funding drugs to be used only sparingly

Financial Times 2/9/2021

How a Small Biotech Survives Amid Looming Antibiotic Crisis

TheStreet 10/24/2020

We need new antimicrobials to prevent the next infectious disease crisis

STAT 8/12/2020

How a crumbling antibiotics infrastructure could yield ‘catastrophe’

PBS NewsHours 7/30/2020

Antibiotic pipeline in peril from coronavirus and incentives system

Axios 5/5/2020

Coronavirus lessons for the fight against ‘superbugs’

Financial Times 5/4/2020

New Genomic Tests Aim to Diagnose Deadly Infections Faster

The New York Times 2/24/2020

Antibiotic drug resistance is creating a global crisis, UN report says

Vox 5/7/2019

Antibiotics Aren’t Profitable Enough for Big Pharma to Make More

Bloomberg Businessweek 5/3/2019

Medicare payment rules hinder the fight against superbugs

STAT 4/17/2019

CARB-X to fund antibiotic development initiative

Homeland Preparedness News 2/11/2019

20 new antibiotics in pipeline to fight superbugs

The Times 2/5/2019

Antibiotics May Soon Become Useless. Now What?

Wired 10/12/2018
Contact for Mentoring:

765 Commonwealth Ave
Boston MA 02215
Google Map


Outterson's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Media Mentions
_
Co-Authors
_
Similar People
_